Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioInvent International AB ( (SE:BINV) ) has shared an announcement.
BioInvent International AB’s 2026 Annual General Meeting approved a refreshed board composition, re-electing four directors, appointing two new members and confirming Leonard Kruimer as chairman while retaining KPMG as auditor, and decided not to pay a dividend for the 2025 financial year. Shareholders also backed a broad long-term stock option program for employees, new warrant issues and authorizations to issue up to 20 percent new shares and transfer treasury shares, measures aimed at bolstering financial flexibility, incentivizing staff and supporting potential acquisitions and future growth initiatives.
The most recent analyst rating on (SE:BINV) stock is a Buy with a SEK90.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a clinical-stage biotechnology company specializing in the discovery and development of novel, first-in-class immuno-modulatory antibodies for cancer therapy. The company runs Phase 1/2 trials in hematological cancers and solid tumors, leveraging its proprietary F.I.R.S.T. technology platform and generating revenue through research collaborations, licensing deals and contract antibody manufacturing for major pharmaceutical partners.
Average Trading Volume: 99,739
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.45B
For detailed information about BINV stock, go to TipRanks’ Stock Analysis page.